Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4349354 | 0.85 | LDHA (0.53) | LDHASLC6A4PPARGPPARACYP1A2 | |
| SCHEMBL4349347 | 0.85 | LDHA (0.53) | LDHASLC6A4PPARGPPARACYP1A2 | |
| SCHEMBL2209892 | 0.77 | HTT (0.51) | LDHATDP1TAS2R14ACHEAPLNR | |
| SCHEMBL2293591 | 0.76 | FFAR1 (0.43) | PPARGPPARA | |
| SCHEMBL14860429 | 0.76 | CYP1A2 (0.46) | LDHACYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL1025521 | 0.74 | ALOX5 (0.52) | LDHATAS2R14ACHE | |
| SCHEMBL3777021 | 0.72 | LDHA (0.49) | LDHASLC6A4PPARGPPARACYP1A2 | |
| SCHEMBL14860143 | 0.71 | EPHX1 (0.48) | — | |
| SCHEMBL14860145 | 0.71 | EPHX1 (0.48) | — | |
| SCHEMBL1527219 | 0.71 | EPHX1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | LDHA 843/4885SLC6A4 2399/4885PPARG 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.